Sonoma Pharmaceuticals (SNOA) Share-based Compensation (2010 - 2026)

Sonoma Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $135000.0 for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 50.0% year-over-year to $135000.0 in Q1 2026; TTM through Mar 2026 was $321000.0, a 43.3% increase from a year earlier, with the FY2026 full-year figure at $255000.0, up 2.0% from the prior year.
• Share-based Compensation rose to $135000.0 in Q1 2026 per SNOA's latest filing, from $121000.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $242000.0 in Q4 2022 and bottomed at $13000.0 in Q4 2024.
• The 5-year median for Share-based Compensation is $108000.0 (2022), against an average of $115176.5.
• Across the five-year window, Share-based Compensation surged 3500.0% in 2022 and sank 90.71% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $242000.0 in 2022, then sank by 42.15% to $140000.0 in 2023, then sank by 90.71% to $13000.0 in 2024, then jumped by 830.77% to $121000.0 in 2025, then rose by 11.57% to $135000.0 in 2026.
• Per Business Quant, the three latest SNOA Share-based Compensation figures stand at $135000.0 (Q1 2026), $121000.0 (Q4 2025), and $39000.0 (Q3 2025).